Thisuri Jayawardena
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Thisuri Jayawardena has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Gerry MacQuillan
Department of Hepatology and Liver Transplant Service Sir Charles Gairdner Hospital Nedlands Australia
3 shared publicationsAron Chakera
Department of Research Sir Charles Gairdner Hospital Perth Western Australia Australia
2 shared publicationsGary Jeffrey
Department of Hepatology and Liver Transplant Service Sir Charles Gairdner Hospital Nedlands Australia
2 shared publicationsSophie Krivinskas
Department of Respiratory Medicine Sir Charles Gairdner Hospital Perth Western Australia Australia
2 shared publicationsTim Mitchell
Medical School, University of Western Australia Nedlands Australia
2 shared publications- Yun Chor Gary Lee
University of Western Australia
2 shared publications
Latest Publications
- 18 July 2025
- Published by Wiley in Liver International
- Vol. 45 (8) , e70228
Response to: Refining HCC Risk Stratification in CHB : Evaluating Predictive Model Applicability in Diverse Populations
- 18 July 2025
- Published by Wiley in Liver International
- Vol. 45 (8) , e70228
Response to: Refining HCC Risk Stratification in CHB : Evaluating Predictive Model Applicability in Diverse Populations
- 29 May 2025
- Published by Wiley in Liver International
- Vol. 45 (7) , e70154
Rationalising Hepatocellular Carcinoma Screening in Chronic Hepatitis B: Evaluation of Predictive Scores in an Australian Cohort
Background and Aims: Several predictive scores have been developed internationally to rationalise hepatocellular carcinoma screening in patients with chronic hepatitis B. This study evaluated the performance of these scores in a large Australian cohort. Methods: A retrospective analysis was undertaken on patients with chronic hepatitis B attending two tertiary hospitals from 1st January 2017 to 30th June 2023. Predictive scores were calculated at baseline and patients were followed for the development of hepatocellular carcinoma. Results: A total of 1080 patients were included. The average age was 48 years, 43% were female, 91% were non‐cirrhotic, and 51% received antivirals. Most patients (62%) were of Asian ethnicity, 13% African, and 9% Caucasian. Twenty‐one patients (1.9%) developed hepatocellular carcinoma during a median follow‐up of 5.2 years. The calculated sensitivity was 90.5% for PAGE‐B and modified PAGE‐B, and 42.9% for REACH‐B. Positive predictive values were below 4%, and negative predictive values exceeded 98% for all scores. The time‐dependent area under the curve at 5 years for PAGE‐B, modified PAGE‐B, and REACH‐B were 0.74, 0.80, and 0.68 respectively. The 5‐year cumulative incidence of hepatocellular carcinoma for patients with low, intermediate, and high PAGE‐B scores was 0.33%, 2.1% and 4.9% respectively (log‐rank, p < 0.001) and for modified PAGE‐B was 0.44%, 1.0% and 7.1% respectively ( p < 0.001). REACH‐B was unable to accurately stratify hepatocellular carcinoma risk ( p = 0.19). Conclusions: In our Australian cohort of diverse ethnicity, cirrhosis and treatment status, both PAGE‐B and modified PAGE‐B scores performed well with respect to hepatocellular carcinoma risk stratification and identifying low‐risk patients who may safely avoid screening.
- 29 May 2025
- Published by Wiley in Liver International
- Vol. 45 (7) , e70154
Rationalising Hepatocellular Carcinoma Screening in Chronic Hepatitis B: Evaluation of Predictive Scores in an Australian Cohort
Background and Aims: Several predictive scores have been developed internationally to rationalise hepatocellular carcinoma screening in patients with chronic hepatitis B. This study evaluated the performance of these scores in a large Australian cohort. Methods: A retrospective analysis was undertaken on patients with chronic hepatitis B attending two tertiary hospitals from 1st January 2017 to 30th June 2023. Predictive scores were calculated at baseline and patients were followed for the development of hepatocellular carcinoma. Results: A total of 1080 patients were included. The average age was 48 years, 43% were female, 91% were non‐cirrhotic, and 51% received antivirals. Most patients (62%) were of Asian ethnicity, 13% African, and 9% Caucasian. Twenty‐one patients (1.9%) developed hepatocellular carcinoma during a median follow‐up of 5.2 years. The calculated sensitivity was 90.5% for PAGE‐B and modified PAGE‐B, and 42.9% for REACH‐B. Positive predictive values were below 4%, and negative predictive values exceeded 98% for all scores. The time‐dependent area under the curve at 5 years for PAGE‐B, modified PAGE‐B, and REACH‐B were 0.74, 0.80, and 0.68 respectively. The 5‐year cumulative incidence of hepatocellular carcinoma for patients with low, intermediate, and high PAGE‐B scores was 0.33%, 2.1% and 4.9% respectively (log‐rank, p < 0.001) and for modified PAGE‐B was 0.44%, 1.0% and 7.1% respectively ( p < 0.001). REACH‐B was unable to accurately stratify hepatocellular carcinoma risk ( p = 0.19). Conclusions: In our Australian cohort of diverse ethnicity, cirrhosis and treatment status, both PAGE‐B and modified PAGE‐B scores performed well with respect to hepatocellular carcinoma risk stratification and identifying low‐risk patients who may safely avoid screening.
- 29 July 2024
- Published by Wiley in Internal Medicine Journal
- Vol. 54 (9) , 1557-1560
Optimising the structure of outpatient clinic letters: insights from a survey of general practitioners and hospital doctors
Outpatient letters are an essential communication tool in healthcare. Yet doctors receive little training on letter writing and what details recipients consider important. We surveyed 106 hospital doctors and 63 general practitioners (GPs), identifying differences in each group's preferences; GPs preferred more structured, detailed letters. Opportunities for feedback, formal templates and advanced software systems can improve communication in outpatient clinics.
- 29 July 2024
- Published by Wiley in Internal Medicine Journal
- Vol. 54 (9) , 1557-1560
Optimising the structure of outpatient clinic letters: insights from a survey of general practitioners and hospital doctors
Outpatient letters are an essential communication tool in healthcare. Yet doctors receive little training on letter writing and what details recipients consider important. We surveyed 106 hospital doctors and 63 general practitioners (GPs), identifying differences in each group's preferences; GPs preferred more structured, detailed letters. Opportunities for feedback, formal templates and advanced software systems can improve communication in outpatient clinics.
- 19 January 2024
- Published by Elsevier in Transplantation Proceedings
- Vol. 56 (1) , 244-248
Successful Liver Retransplantation in a Patient With Disseminated Aspergillosis and Nocardiosis: A Case Report
- 19 January 2024
- Published by Elsevier in Transplantation Proceedings
- Vol. 56 (1) , 244-248
Successful Liver Retransplantation in a Patient With Disseminated Aspergillosis and Nocardiosis: A Case Report
- Open Access
- 17 October 2022
- Published by Wiley in Respirology Case Reports
- Vol. 10 (11) , e01055
Antibiotic administration via indwelling peritoneal catheter to treat infected malignant ascites
Indwelling pleural catheter is an established management for malignant pleural effusions. Extending its use to patients with malignant ascites by insertion of a catheter intraperitoneally enables regular outpatient drainage and improves quality‐of‐life. However, indwelling pleural/peritoneal catheter (IPC/IPeC) is associated with catheter‐related infections, traditionally managed with systemic antibiotics and occasionally requires catheter removal. Direct administration of antibiotics intra‐abdominally via peritoneal dialysis (PD) catheters is a well‐established, efficacious practice in PD‐related peritonitis and minimizes systemic adverse effects. We applied the same principles to a patient with peritoneal mesothelioma who developed peritonitis 3 weeks after insertion of IPeC. Intraperitoneal vancomycin was administered via, and compatible with, the IPeC. The patient tolerated the treatment without adverse effects and made a full recovery without requiring catheter removal.
- 17 October 2022
- Published by Wiley in Respirology Case Reports
- Vol. 10 (11) , e01055
Open AccessAntibiotic administration via indwelling peritoneal catheter to treat infected malignant ascites
Indwelling pleural catheter is an established management for malignant pleural effusions. Extending its use to patients with malignant ascites by insertion of a catheter intraperitoneally enables regular outpatient drainage and improves quality‐of‐life. However, indwelling pleural/peritoneal catheter (IPC/IPeC) is associated with catheter‐related infections, traditionally managed with systemic antibiotics and occasionally requires catheter removal. Direct administration of antibiotics intra‐abdominally via peritoneal dialysis (PD) catheters is a well‐established, efficacious practice in PD‐related peritonitis and minimizes systemic adverse effects. We applied the same principles to a patient with peritoneal mesothelioma who developed peritonitis 3 weeks after insertion of IPeC. Intraperitoneal vancomycin was administered via, and compatible with, the IPeC. The patient tolerated the treatment without adverse effects and made a full recovery without requiring catheter removal.
- Open Access
- 26 August 2021
- Published by Wiley in Respirology Case Reports
- Vol. 9 (9) , e0837
Conservative management of a complete primary spontaneous pneumothorax
Large primary spontaneous pneumothorax (PSP) has traditionally been managed with needle aspiration, chest tube drainage and, in refractory cases, thoracic surgery. A recent randomized trial, however, provided evidence that a conservative observational approach was safe and 85% of patients recovered without requiring pleural drainage interventions. A conservative approach provided similar re‐expansion rates at 8 weeks compared with chest tube drainage and offered the advantages of early hospital discharge, fewer days off work and avoidance of procedural risks. Nonetheless, clinicians are understandably anxious with conservative (non‐drainage) management for patients with very large pneumothorax. Here, we report a patient with a right‐sided PSP and total lung collapse that was managed successfully without intervention with minimal time in hospital or off work.
- 26 August 2021
- Published by Wiley in Respirology Case Reports
- Vol. 9 (9) , e0837
Open AccessConservative management of a complete primary spontaneous pneumothorax
Large primary spontaneous pneumothorax (PSP) has traditionally been managed with needle aspiration, chest tube drainage and, in refractory cases, thoracic surgery. A recent randomized trial, however, provided evidence that a conservative observational approach was safe and 85% of patients recovered without requiring pleural drainage interventions. A conservative approach provided similar re‐expansion rates at 8 weeks compared with chest tube drainage and offered the advantages of early hospital discharge, fewer days off work and avoidance of procedural risks. Nonetheless, clinicians are understandably anxious with conservative (non‐drainage) management for patients with very large pneumothorax. Here, we report a patient with a right‐sided PSP and total lung collapse that was managed successfully without intervention with minimal time in hospital or off work.
- 18 December 2018
- Published by Wiley in Vox Sanguinis
- Vol. 114 (2) , 107-116
Modelling the risk of transfusion‐transmitted syphilis: a reconsideration of blood donation testing strategies
Background and Objectives: Donor syphilis testing began in the 1940s amidst widespread transfusion‐transmitted syphilis (TTS). Since then, the introduction of penicillin, pre‐donation screening questionnaires and improved storage conditions have contributed to reducing transmission risk. Consequently, universal testing may no longer be cost‐effective. This study analysed alternative options for donor syphilis testing to determine the optimal strategy.Materials and Methods: A model was developed using conservative parameter estimates for factors affecting TTS and 2009‐2015 Australian donations to calculate risk outcomes (TTS infections, tertiary syphilis in recipients and transfusion‐associated congenital syphilis) and cost‐effectiveness of alternative testing strategies. The strategies modelled were as follows: universal testing, targeted‐testing of high‐risk groups (males ≤50 years old and first‐time donors) and no testing.Results: The estimated risk of TTS is one in 49·5 million transfusions for universal testing, one in 6 million for targeted‐testing of males ≤50 years old, one in 4 million for targeted‐testing of first‐time donors and one in 2·8 million for no testing. For all strategies, the risk of tertiary and congenital syphilis is <1 in 100 million. Universal testing is the least cost‐effective strategy with an incremental cost‐effectiveness ratio (ICER) estimated at $538·5 million per disability‐adjusted life year averted.Conclusion: Universal testing is not required to maintain the risk of TTS within tolerable limits and is estimated to greatly exceed acceptable ICERs for blood safety interventions. However, despite a strong economic and risk‐based rationale, given the epidemiology of syphilis in Australia is changing, feedback from critical stakeholders is not currently supportive of reducing testing.
- 18 December 2018
- Published by Wiley in Vox Sanguinis
- Vol. 114 (2) , 107-116
Modelling the risk of transfusion‐transmitted syphilis: a reconsideration of blood donation testing strategies
Background and Objectives: Donor syphilis testing began in the 1940s amidst widespread transfusion‐transmitted syphilis (TTS). Since then, the introduction of penicillin, pre‐donation screening questionnaires and improved storage conditions have contributed to reducing transmission risk. Consequently, universal testing may no longer be cost‐effective. This study analysed alternative options for donor syphilis testing to determine the optimal strategy.Materials and Methods: A model was developed using conservative parameter estimates for factors affecting TTS and 2009‐2015 Australian donations to calculate risk outcomes (TTS infections, tertiary syphilis in recipients and transfusion‐associated congenital syphilis) and cost‐effectiveness of alternative testing strategies. The strategies modelled were as follows: universal testing, targeted‐testing of high‐risk groups (males ≤50 years old and first‐time donors) and no testing.Results: The estimated risk of TTS is one in 49·5 million transfusions for universal testing, one in 6 million for targeted‐testing of males ≤50 years old, one in 4 million for targeted‐testing of first‐time donors and one in 2·8 million for no testing. For all strategies, the risk of tertiary and congenital syphilis is <1 in 100 million. Universal testing is the least cost‐effective strategy with an incremental cost‐effectiveness ratio (ICER) estimated at $538·5 million per disability‐adjusted life year averted.Conclusion: Universal testing is not required to maintain the risk of TTS within tolerable limits and is estimated to greatly exceed acceptable ICERs for blood safety interventions. However, despite a strong economic and risk‐based rationale, given the epidemiology of syphilis in Australia is changing, feedback from critical stakeholders is not currently supportive of reducing testing.